Last reviewed · How we verify
Dihydromyricetin
Dihydromyricetin is a Small molecule drug developed by University of Southern California. It is currently in Phase 2 development. Also known as: Ampelopsis grossedentata Extract.
Dihydromyricetin, also known as ampelopsin, is a small molecule flavanonol extracted from various plant species, including the Japanese raisin tree. It has been studied in clinical trials for its potential effects on conditions such as alcohol drinking, alcohol intoxication, and type 2 diabetes mellitus, as well as its ability to alleviate alcohol hangover symptoms.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Dihydromyricetin |
|---|---|
| Also known as | Ampelopsis grossedentata Extract |
| Sponsor | University of Southern California |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase I, Dose-Escalation Study of Dihydromyricetin (DHM) to Treat Alcohol-Associated Liver Disease (PHASE1)
- A Clinical Study to Assess the Effects of JoyRise Recovery Powder on Mitigating Alcohol Aftereffects. (NA)
- Effect of Dihydromirycetin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes Mellitus (PHASE2)
- Efficacy of the Dietary Food Supplement ALCOFILTRUM in Alleviating Alcohol Hangover Symptoms (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dihydromyricetin CI brief — competitive landscape report
- Dihydromyricetin updates RSS · CI watch RSS
- University of Southern California portfolio CI
Frequently asked questions about Dihydromyricetin
What is Dihydromyricetin?
Who makes Dihydromyricetin?
Is Dihydromyricetin also known as anything else?
What development phase is Dihydromyricetin in?
Related
- Manufacturer: University of Southern California — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Ampelopsis grossedentata Extract
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing